We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ORIPRO (Orion Laboratories Pty Ltd T/A Perrigo Australia)
Product name
ORIPRO
Date registered
Evaluation commenced
Decision date
Approval time
189 working days (255)
Active ingredients
progesterone
Registration type
EOI
Indication
ORIPRO (pessaries) is now also indicated for prevention of preterm birth in singleton pregnancies at risk due to:
- Shortened cervix (midtrimester sonographic cervix ≤25 mm) and/or
- Where there is a history of spontaneous preterm birth.